Protara Therapeutics Shares Findings from THRIVE-1 Study
Protara Therapeutics, Inc. (Nasdaq: TARA) has recently revealed important results from their THRIVE-1 study, aimed at addressing significant health issues. This prospective observational study examined the prevalence of choline deficiency and liver injury in patients who depend on parenteral support (PS). The findings were presented at the European Society for Clinical Nutrition and Metabolism Congress.
Study Results Highlight Choline Deficiency Issues
The study revealed that an alarming 78% of participants relying on parenteral support were found to be deficient in choline. Furthermore, 63% of these individuals showed signs of liver dysfunction, which included conditions like steatosis, cholestasis, and hepatobiliary injury. These findings emphasize the urgent need for intravenous (IV) choline supplementation for this at-risk population.
The Importance of IV Choline Chloride
Protara Therapeutics is leading the charge in developing IV Choline Chloride, an investigational therapy aimed at fulfilling this critical unmet medical need. Choline is vital for maintaining liver health, and a deficiency can result in severe complications, including liver injury and various neuropsychological disorders.
Expert Opinions and Future Directions
Dr. Palle Bekker Jeppesen, a Clinical Professor with expertise in intestinal failure and liver diseases, commented on the study's findings, noting that many patients who rely on parenteral support could greatly benefit from IV Choline Chloride. The potential for an IV formulation is particularly crucial for those unable to obtain sufficient choline through oral or enteral nutrition.
Protara's Commitment and Upcoming Initiatives
Jesse Shefferman, CEO of Protara Therapeutics, expressed the company's commitment to launching the first approved IV choline product, especially in light of the current lack of available options. Protara plans to start a pivotal pharmacokinetic trial for IV Choline Chloride in early 2025.
Overview of the THRIVE-1 Study
The THRIVE-1 study was thorough, involving 78 patients with intestinal failure who depend on parenteral support. The results highlight a significant health gap, indicating a pressing need for choline supplementation in these individuals.
Understanding IV Choline Chloride
IV Choline Chloride is being positioned as an innovative therapeutic solution. Approximately 80% of patients on parenteral support are choline deficient, and the introduction of this therapy could help avert serious liver damage and failure.
Implications for Patient Care
This investigation comes at a crucial time, addressing a major gap in the care of patients on parenteral support, who number around 40,000 in the U.S. alone. The implications of these findings could transform how healthcare providers develop treatment strategies for these patients.
About Protara Therapeutics, Inc.
Protara is committed to improving treatment options for individuals facing cancer and rare diseases. With a varied portfolio, their lead candidate, TARA-002, signifies a notable advancement in treating specific cancer types. The company remains dedicated to ensuring that patients receive the essential therapies they need.
Frequently Asked Questions
What were the key findings of the THRIVE-1 study?
The study found that 78% of patients on parenteral support were choline deficient, with 63% of those experiencing liver dysfunction.
What is IV Choline Chloride?
IV Choline Chloride is an investigational therapy aimed at providing choline supplementation to patients unable to meet their needs through oral or enteral means.
How does choline deficiency affect patients?
Choline deficiency can lead to severe health issues, including liver injuries, neuropsychological impairments, and other complications.
Why is there a need for IV Choline products?
There are currently no approved IV choline products worldwide for parenteral support patients, despite medical recommendations advocating for choline treatment.
What are Protara's future plans?
Protara is planning to initiate a pivotal trial for IV Choline Chloride in early 2025, aiming to bring the first approved formulation to market.
